A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

PMID- 28838198
DA  - 20170825
DCOM- 20170905
LR  - 20170906
IS  - 1537-6613 (Electronic)
IS  - 0022-1899 (Linking)
VI  - 216
IP  - suppl_1
DP  - 2017 Jul 01
TI  - Lessons From Globally Coordinated Cessation of Serotype 2 Oral Poliovirus Vaccine
      for the Remaining Serotypes.
PG  - S168-S175
LID - 10.1093/infdis/jix128 [doi]
AB  - Background: Comparing model expectations with the experience of oral poliovirus
      vaccine (OPV) containing serotype 2 (OPV2) cessation can inform risk management
      for the expected cessation of OPV containing serotypes 1 and 3 (OPV13). Methods: 
      We compare the expected post-OPV2-cessation OPV2-related viruses from models with
      the evidence available approximately 6 months after OPV2 cessation. We also model
      the trade-offs of use vs nonuse of monovalent OPV (mOPV) for outbreak response
      considering all 3 serotypes. Results: Although too early to tell definitively,
      the observed die-out of OPV2-related viruses in populations that attained
      sufficiently intense trivalent OPV (tOPV) use prior to OPV2 cessation appears
      consistent with model expectations. As expected, populations that did not
      intensify tOPV use prior to OPV2 cessation show continued circulation of serotype
      2 vaccine-derived polioviruses (VDPVs). Failure to aggressively use mOPV to
      respond to circulating VDPVs results in a high risk of uncontrolled outbreaks
      that would require restarting OPV. Conclusions: Ensuring a successful endgame
      requires more aggressive OPV cessation risk management than has occurred to date 
      for OPV2 cessation. This includes maintaining high population immunity to
      transmission up until OPV13 cessation, meeting all prerequisites for OPV
      cessation, and ensuring sufficient vaccine supply to prevent and respond to
FAU - Thompson, Kimberly M
AU  - Thompson KM
AD  - Kid Risk, Inc.
AD  - University of Central Florida, College of Medicine, Orlando.
FAU - Duintjer Tebbens, Radboud J
AU  - Duintjer Tebbens RJ
AD  - Kid Risk, Inc.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Infect Dis
JT  - The Journal of infectious diseases
JID - 0413675
RN  - 0 (Poliovirus Vaccine, Oral)
SB  - IM
MH  - Disease Outbreaks/*prevention & control
MH  - *Global Health
MH  - Humans
MH  - Models, Biological
MH  - Models, Statistical
MH  - *Poliomyelitis/epidemiology/prevention & control/virology
MH  - Poliovirus/*immunology
MH  - *Poliovirus Vaccine, Oral/administration & dosage/adverse effects/therapeutic use
MH  - Risk
MH  - Serogroup
OT  - disease outbreaks
OT  - dynamic modeling
OT  - eradication
OT  - polio
EDAT- 2017/08/26 06:00
MHDA- 2017/09/07 06:00
CRDT- 2017/08/26 06:00
PHST- 2016/12/19 [received]
PHST- 2017/03/13 [accepted]
AID - 3935076 [pii]
AID - 10.1093/infdis/jix128 [doi]
PST - ppublish
SO  - J Infect Dis. 2017 Jul 1;216(suppl_1):S168-S175. doi: 10.1093/infdis/jix128.